US-based brain-computer interface startup Axoft has secured $55 million in a new funding round as it begins human clinical trials for its neural implant technology in China. This marks what is believed to be the first time an American brain implant company has tested its devices on patients within the Chinese market, signaling a strategic push into international medical landscapes.
The company's technology centers on high-bandwidth implants designed to interface directly with the human brain, aiming to treat various neurological conditions. The fresh capital will support ongoing research and development as Axoft navigates complex regulatory and clinical requirements across global markets.
Source: Bloomberg